QSAM Biosciences, Inc. (UNQ: A408WA)
Health Care · Biotechnology · US
€—
— today · — 1Y
QSAM Biosciences, Inc. (UNQ: A408WA) operates in the Biotechnology industry within the Health Care sector.
trading between 12.70K and 14.91K.
Tweenvest scores QSAM Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
A408WA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- €14,910.00
- 52-week low
- €12,700.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 4
- Next earnings
- —
About QSAM Biosciences, Inc.
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
- ISIN
- US74738N3017
- Founded
- 2004
- Listed since
- Aug 13, 2012
- Exchange
- Unquoted Security
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.